Prospective clinical trials in adults with T-cell lymphoblastic disease
| Reference . | Number with T-cell disease . | Disease type . | Treatment given . | CR and OS rates . |
|---|---|---|---|---|
| 6 | 90 | ALL | LAL0496 protocol with CNS RT | CR-NS, OS-NS |
| 52 | 87 | ALL | ALL 90, 93, and 97 protocols of JALSG; CNS RT for high WCC; alloHCT for almost half | CR 75.8% |
| OS 35% (5 y) | ||||
| 8 | 744 | ALL | GMALL 05/93, 06/99, and 07/2003; No alloHCT in CR1 | CR 86% |
| OS 47% (10 y) | ||||
| 50 | 76 | ALL | GRAALL 2003; CNS RT for all; alloHCT for high-risk patients | CR 99% |
| EFS 62% (42 mo) | ||||
| 4 | 356 | ALL | UKALL XII/E2993; alloHCT for those with sibling donor; RCT for the rest chemo vs autograft CNS RT for chemo only arm | CR 94% |
| OS 48% (5 y) | ||||
| 38 | 24 | ALL | HyperCVAD; alloHCT for high-risk patients (4%) | CR 89% |
| OS 47% (5 y) | ||||
| 51 | 40 | ALL/LBL | HyperCVAD plus nelarabine | CR 91% |
| OS 63% (3 y) | ||||
| 9 | 111 | ALL/LBL | HyperCVAD, HyperCVAD plus nelarabine, or augmented BFM | CR 88% |
| OS 52% (5 y) |
| Reference . | Number with T-cell disease . | Disease type . | Treatment given . | CR and OS rates . |
|---|---|---|---|---|
| 6 | 90 | ALL | LAL0496 protocol with CNS RT | CR-NS, OS-NS |
| 52 | 87 | ALL | ALL 90, 93, and 97 protocols of JALSG; CNS RT for high WCC; alloHCT for almost half | CR 75.8% |
| OS 35% (5 y) | ||||
| 8 | 744 | ALL | GMALL 05/93, 06/99, and 07/2003; No alloHCT in CR1 | CR 86% |
| OS 47% (10 y) | ||||
| 50 | 76 | ALL | GRAALL 2003; CNS RT for all; alloHCT for high-risk patients | CR 99% |
| EFS 62% (42 mo) | ||||
| 4 | 356 | ALL | UKALL XII/E2993; alloHCT for those with sibling donor; RCT for the rest chemo vs autograft CNS RT for chemo only arm | CR 94% |
| OS 48% (5 y) | ||||
| 38 | 24 | ALL | HyperCVAD; alloHCT for high-risk patients (4%) | CR 89% |
| OS 47% (5 y) | ||||
| 51 | 40 | ALL/LBL | HyperCVAD plus nelarabine | CR 91% |
| OS 63% (3 y) | ||||
| 9 | 111 | ALL/LBL | HyperCVAD, HyperCVAD plus nelarabine, or augmented BFM | CR 88% |
| OS 52% (5 y) |
BFM, Berlin Frankfurt Munster protocol; CNS RT, CNS radiotherapy; JALSG, Japan Adult Leukemia Study Group; NS, not significant; RCT, randomized controlled trial.